Reverse peptide vaccine
AssigneeEmergex Vaccines Holding Ltd.
InventorsRamila Philip, Richard David Perrins, Xiaofang Huang, Thomas Rademacher, Christopher Upton
Life of this patent
Estimating the term…
Abstract
The invention relates to vaccine compositions comprising peptides encoded by an open reading frame (ORF) encoded by at least part of the genome of a ssRNA virus in the opposite sense to positive sense RNA capable of translation, and the use of such compositions for the treatment and prevention of viral infection.
Claims21
A vaccine composition comprising an immunogenic peptide comprising an influenza A CD8+ T cell epitope, wherein the CD8+ T cell epitope is selected from any one of SEQ ID NOs:
- 16 to 18 and 20 to 53, or a variant thereof having at least 80% identity to any one of SEQ ID NOs:
- 16 to 18 and 20 to 53, said variant comprising an epitope that is recognized by a CD8+ T cell, and wherein the immunogenic peptide:
- (i) is about 8 to about 30 amino acids in length;
- and
- (ii) is attached to a nanoparticle.
A method preventing or treating an influenza infection, comprising administering a vaccine composition to an individual infected with, or at risk of being infected with, an influenza A virus, wherein said vaccine composition comprises:
- an immunogenic peptide comprising an influenza A CD8+ T cell epitope, wherein the CD8+ T cell epitope is selected from any one of SEQ ID NOs:
- 16 to 18 and 20 to 53, or a variant thereof having at least 80% identity to any one of SEQ ID NOs:
- 16 to 18 and 20 to 53, said variant comprising an epitope that is recognized by a CD8+ T cell, and wherein the immunogenic peptide:
- (i) is about 8 to about 30 amino acids in length;
- and
- (ii) is attached to a nanoparticle, and wherein the nanoparticle is coated with a coating that includes N-acetylglucosamine (GlcNAc).
A method of inducing an immune response in an individual, comprising administering to the individual an immunogenic peptide comprising an influenza A CD8+ T cell epitope selected from the group consisting of any one of SEQ ID NOs:
- 16 to 18 and 20 to 53, or a variant thereof having at least 80% identity to any one of SEQ ID NOs:
- 16 to 18 and 20 to 53, said variant comprising an epitope that is recognized by a CD8+ T cell, wherein the peptide is about 8 to about 30 amino acids in length and is attached to a nanoparticle and wherein the nanoparticle is coated with a coating that includes N-acetylglucosamine (GlcNAc).
Dependencies are inferred from the claim text.